<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>704</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>12163263</PubmedId>
            <Abstract>Mucosal immunity is critical for protection from viral infections. We attempted to activate mucosal cytotoxic T lymphocytes (CTLs) specific for influenza A virus nucleoprotein (NP) which play an important role in protective immunity. It has been shown that dendritic cells (DCs) activated by signaling via CD40-CD40 ligand (CD40L) interaction are required for the differentiation of naive CD8(+) T cells into antigen-specific CTLs in a non-mucosal environment. We herein inoculated mice intranasally with an anti-CD40 monoclonal antibody (anti-CD40 mAb) and NP366-374 peptide, corresponding to a CTL epitope on NP, encapsulated in liposome (liposomal NP366-374) to induce protective CTL responses against influenza A virus. Intranasal but not subcutaneous immunization with liposomal NP366-374 effectively induced mucosal immunity to reduce virus replication in the lung, suggesting that anti-CD40 mAb also functioned as a mucosal adjuvant. Interestingly, neither MHC class I- nor class II-deficient mice immunized intranasally with these materials were resistant to the infection. Since anti-CD40 mAb was considered to help replace CD4(+) T cells, another help of CD4(+) T cells are presumably required for the induction of CTL activity in the lung. This approach may prove promising for developing vaccines to induce mucosal CTL responses, and seems to highlight differences between mucosal and non-mucosal immunity.</Abstract>
            <ArticleYear>2002</ArticleYear>
            <ArticlePages>3123-9</ArticlePages>
            <ArticleTitle>Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Ninomiya</LastName>
                    <ForeName>Ai</ForeName>
                </Author>
                <Author>
                    <LastName>Ogasawara</LastName>
                    <ForeName>Kazumasa</ForeName>
                </Author>
                <Author>
                    <LastName>Kajino</LastName>
                    <ForeName>Kiichi</ForeName>
                </Author>
                <Author>
                    <LastName>Takada</LastName>
                    <ForeName>Ayato</ForeName>
                </Author>
                <Author>
                    <LastName>Kida</LastName>
                    <ForeName>Hiroshi</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Disease Control, Hokkaido University Graduate School of Veterinary Medicine, Sapporo 060-0818, Japan.</Affiliations>
            <ArticleChemicalList>Adjuvants, Immunologic;Antibodies, Monoclonal;CD40 Antigens;Epitopes;Histocompatibility Antigens Class II;Influenza Vaccines;Liposomes;Nucleocapsid Proteins;Nucleoproteins;Peptide Fragments;Vaccines, Subunit;Vaccines, Synthetic;Viral Core Proteins;beta 2-Microglobulin;nucleoprotein (366-374), influenza virus</ArticleChemicalList>
            <ArticleMeshHeadingsList>Adjuvants, Immunologic; Administration, Intranasal; Animals; Antibodies, Monoclonal(administration &amp; dosage; immunology); CD4-Positive T-Lymphocytes(immunology); CD40 Antigens(immunology); Epitopes(administration &amp; dosage; immunology); Female; Genes, MHC Class II; Histocompatibility Antigens Class II(genetics); Immunity, Mucosal(immunology); Immunization Schedule; Influenza A virus(immunology; physiology); Influenza Vaccines(administration &amp; dosage; immunology); Kinetics; Liposomes(administration &amp; dosage); Lung(immunology; virology); Mice; Mice, Inbred C57BL; Mice, Knockout; Nucleocapsid Proteins; Nucleoproteins(administration &amp; dosage; immunology); Peptide Fragments(administration &amp; dosage; immunology); T-Lymphocytes, Cytotoxic(immunology); Vaccination(methods); Vaccines, Subunit(administration &amp; dosage; immunology); Vaccines, Synthetic(administration &amp; dosage; immunology); Viral Core Proteins(administration &amp; dosage; immunology); Virus Replication; beta 2-Microglobulin(deficiency; genetics)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>20</Volume>
                <Issue>25-26</Issue>
                <Title>Vaccine</Title>
                <Issn>1873-2518</Issn>
                <MedlineTa>Vaccine</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>NP366-374</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ASNENMDAM</LinearSequence>
                        <StartingPosition>366</StartingPosition>
                        <EndingPosition>374</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P22435.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>41857</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 3124</LocationOfData>
                <EpitopeId>4578</EpitopeId>
                <ReferenceStartingPosition>366</ReferenceStartingPosition>
                <ReferenceEndingPosition>374</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1, Figure 1, 2,4</LocationOfData>
                        <TCellId>6992</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                                <Age>5 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>ASNENMDAM</LinearSequence>
                                            <StartingPosition>366</StartingPosition>
                                            <EndingPosition>374</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P22435.2</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>41857</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>NP366-374</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Liposomes</Adjuvant>
                                <Route>Intranasal</Route>
                                <DoseSchedule>Mice were immunized with 50 microliters of liposomal peptide with or without anti-CD40 mAb (250 micrograms per mouse) at 2-week intervals.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>To assess the potential of anti-CD40 mAb as a mucosaladjuvant, mice were immunized with liposomal NP 366-374alone or together with anti-CD40 mAb and then challengedintranasally with a live influenza virus.</ImmunizationComments>
                        </Immunization>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Influenza A virus H3N2</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>41857</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>182</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>9</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>9</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Virus titers in the lungs on day 5 after the challenge were determined from the numbers of plaques.  Virus titers of mice immunized with liposomal NP366-374 were significantly lower than controls.  Three intranasal immunizations was shown to confer significant protection, while subcutaneous immunization provided no effective immunityin the lung.  Also, this protective immunity was shown to last at least 8 weeks.  When tested, neither MHC class I- nor class II-deficient mice immunized intranasally with these materials were resistant to the infection, suggesting that both CD4+ and CD8+ cells may be involved in the clearance of the virus from mouse lungs.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

